Industry Research Reports
Home > Reports > Service & Software > Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Industry: Service & Software
Published Date: 2025-07-24
Pages: 160 Pages
Report ld: 4799025
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Multi-Cancer Early Screening Market Size(US$)
CAGR 2025-2031
17.0%
Market Size,2031
USD 3,346
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 1,305 million
Market Forecast in 2031(Value)
US$ 3,346 million
CAGR
17.0%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Multi-Cancer Early Screening is an early screening technology that simultaneously evaluates the risk of multiple cancers through a single test (such as a blood sample). Its core value lies in breaking through the limitations of traditional cancer screening (such as single cancer detection, invasive procedures, etc.), achieving "one tube of blood to test multiple cancers", significantly improving the early detection rate of cancer, and reducing the late diagnosis rate and mortality rate.
North American market for Multi-Cancer Early Screening was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Multi-Cancer Early Screening was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Multi-Cancer Early Screening was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of Multi-Cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life, Berry Genomics, Singlera Genomics, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Multi-Cancer Early Screening, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Multi-Cancer Early Screening by region & country, by Type, and by Application.
The Multi-Cancer Early Screening market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multi-Cancer Early Screening.
MARKET SEGMENTATION
By Company
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
- Surexam Bio-Tech Co.,Ltd.
- HaploX
- HefeiLaierBiotechnologyCo.,Ltd
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- cfDNA Methylation
- Low-pass WGS
- Protein Marker Combination
- Multi-omics Integrated Analysis
Segment by Application
- Medical Institutions
- Physical Examination Centers
Segment by Category
- IVD（In Vitro Diagnostics）
- LDT (Laboratory Developed Test)
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Multi-Cancer Early Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Multi-Cancer Early Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Multi-Cancer Early Screening in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Multi-Cancer Early Screening Product Introduction
1.2 Global Multi-Cancer Early Screening Market Size Forecast (2020-2031)
1.3 Multi-Cancer Early Screening Market Trends & Drivers
1.3.1 Multi-Cancer Early Screening Industry Trends
1.3.2 Multi-Cancer Early Screening Market Drivers & Opportunity
1.3.3 Multi-Cancer Early Screening Market Challenges
1.3.4 Multi-Cancer Early Screening Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Multi-Cancer Early Screening Players Revenue Ranking (2024)
2.2 Global Multi-Cancer Early Screening Revenue by Company (2020-2025)
2.3 Key Companies Multi-Cancer Early Screening Manufacturing Base Distribution and Headquarters
2.4 Key Companies Multi-Cancer Early Screening Product Offered
2.5 Key Companies Time to Begin Mass Production of Multi-Cancer Early Screening
2.6 Multi-Cancer Early Screening Market Competitive Analysis
2.6.1 Multi-Cancer Early Screening Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Multi-Cancer Early Screening Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-Cancer Early Screening as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 cfDNA Methylation
3.1.2 Low-pass WGS
3.1.3 Protein Marker Combination
3.1.4 Multi-omics Integrated Analysis
3.2 Global Multi-Cancer Early Screening Sales Value by Type
3.2.1 Global Multi-Cancer Early Screening Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Multi-Cancer Early Screening Sales Value, by Type (2020-2031)
3.2.3 Global Multi-Cancer Early Screening Sales Value, by Type (%) (2020-2031)
4 Segmentation by Commercial Mode
4.1 Introduction by Commercial Mode
4.1.1 IVD（In Vitro Diagnostics）
4.1.2 LDT (Laboratory Developed Test)
4.2 Global Multi-Cancer Early Screening Sales Value by Commercial Mode
4.2.1 Global Multi-Cancer Early Screening Sales Value by Commercial Mode (2020 VS 2024 VS 2031)
4.2.2 Global Multi-Cancer Early Screening Sales Value, by Commercial Mode (2020-2031)
4.2.3 Global Multi-Cancer Early Screening Sales Value, by Commercial Mode (%) (2020-2031)
5 Segmentation by Application
5.1 Introduction by Application
5.1.1 Medical Institutions
5.1.2 Physical Examination Centers
5.2 Global Multi-Cancer Early Screening Sales Value by Application
5.2.1 Global Multi-Cancer Early Screening Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Multi-Cancer Early Screening Sales Value, by Application (2020-2031)
5.2.3 Global Multi-Cancer Early Screening Sales Value, by Application (%) (2020-2031)
6 Segmentation by Region
6.1 Global Multi-Cancer Early Screening Sales Value by Region
6.1.1 Global Multi-Cancer Early Screening Sales Value by Region: 2020 VS 2024 VS 2031
6.1.2 Global Multi-Cancer Early Screening Sales Value by Region (2020-2025)
6.1.3 Global Multi-Cancer Early Screening Sales Value by Region (2026-2031)
6.1.4 Global Multi-Cancer Early Screening Sales Value by Region (%), (2020-2031)
6.2 North America
6.2.1 North America Multi-Cancer Early Screening Sales Value, 2020-2031
6.2.2 North America Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
6.3 Europe
6.3.1 Europe Multi-Cancer Early Screening Sales Value, 2020-2031
6.3.2 Europe Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
6.4 Asia Pacific
6.4.1 Asia Pacific Multi-Cancer Early Screening Sales Value, 2020-2031
6.4.2 Asia Pacific Multi-Cancer Early Screening Sales Value by Region (%), 2024 VS 2031
6.5 South America
6.5.1 South America Multi-Cancer Early Screening Sales Value, 2020-2031
6.5.2 South America Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
6.6 Middle East & Africa
6.6.1 Middle East & Africa Multi-Cancer Early Screening Sales Value, 2020-2031
6.6.2 Middle East & Africa Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
7 Segmentation by Key Countries/Regions
7.1 Key Countries/Regions Multi-Cancer Early Screening Sales Value Growth Trends, 2020 VS 2024 VS 2031
7.2 Key Countries/Regions Multi-Cancer Early Screening Sales Value, 2020-2031
7.3 United States
7.3.1 United States Multi-Cancer Early Screening Sales Value, 2020-2031
7.3.2 United States Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.3.3 United States Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.4 Europe
7.4.1 Europe Multi-Cancer Early Screening Sales Value, 2020-2031
7.4.2 Europe Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.4.3 Europe Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.5 China
7.5.1 China Multi-Cancer Early Screening Sales Value, 2020-2031
7.5.2 China Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.5.3 China Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.6 Japan
7.6.1 Japan Multi-Cancer Early Screening Sales Value, 2020-2031
7.6.2 Japan Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.6.3 Japan Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.7 South Korea
7.7.1 South Korea Multi-Cancer Early Screening Sales Value, 2020-2031
7.7.2 South Korea Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.7.3 South Korea Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.8 Southeast Asia
7.8.1 Southeast Asia Multi-Cancer Early Screening Sales Value, 2020-2031
7.8.2 Southeast Asia Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.8.3 Southeast Asia Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
7.9 India
7.9.1 India Multi-Cancer Early Screening Sales Value, 2020-2031
7.9.2 India Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
7.9.3 India Multi-Cancer Early Screening Sales Value by Application, 2024 VS 2031
8 Company Profiles
8.1 Guardant Health
8.1.1 Guardant Health Profile
8.1.2 Guardant Health Main Business
8.1.3 Guardant Health Multi-Cancer Early Screening Products, Services and Solutions
8.1.4 Guardant Health Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.1.5 Guardant Health Recent Developments
8.2 Exact Sciences
8.2.1 Exact Sciences Profile
8.2.2 Exact Sciences Main Business
8.2.3 Exact Sciences Multi-Cancer Early Screening Products, Services and Solutions
8.2.4 Exact Sciences Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.2.5 Exact Sciences Recent Developments
8.3 Freenome
8.3.1 Freenome Profile
8.3.2 Freenome Main Business
8.3.3 Freenome Multi-Cancer Early Screening Products, Services and Solutions
8.3.4 Freenome Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.3.5 Freenome Recent Developments
8.4 Epiginomics AG
8.4.1 Epiginomics AG Profile
8.4.2 Epiginomics AG Main Business
8.4.3 Epiginomics AG Multi-Cancer Early Screening Products, Services and Solutions
8.4.4 Epiginomics AG Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.4.5 Epiginomics AG Recent Developments
8.5 Bio-techne
8.5.1 Bio-techne Profile
8.5.2 Bio-techne Main Business
8.5.3 Bio-techne Multi-Cancer Early Screening Products, Services and Solutions
8.5.4 Bio-techne Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.5.5 Bio-techne Recent Developments
8.6 ThriveEarlier Detection
8.6.1 ThriveEarlier Detection Profile
8.6.2 ThriveEarlier Detection Main Business
8.6.3 ThriveEarlier Detection Multi-Cancer Early Screening Products, Services and Solutions
8.6.4 ThriveEarlier Detection Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.6.5 ThriveEarlier Detection Recent Developments
8.7 GRAIL, Inc.
8.7.1 GRAIL, Inc. Profile
8.7.2 GRAIL, Inc. Main Business
8.7.3 GRAIL, Inc. Multi-Cancer Early Screening Products, Services and Solutions
8.7.4 GRAIL, Inc. Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.7.5 GRAIL, Inc. Recent Developments
8.8 CellMax life
8.8.1 CellMax life Profile
8.8.2 CellMax life Main Business
8.8.3 CellMax life Multi-Cancer Early Screening Products, Services and Solutions
8.8.4 CellMax life Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.8.5 CellMax life Recent Developments
8.9 Berry Genomics
8.9.1 Berry Genomics Profile
8.9.2 Berry Genomics Main Business
8.9.3 Berry Genomics Multi-Cancer Early Screening Products, Services and Solutions
8.9.4 Berry Genomics Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.9.5 Berry Genomics Recent Developments
8.10 Singlera Genomics
8.10.1 Singlera Genomics Profile
8.10.2 Singlera Genomics Main Business
8.10.3 Singlera Genomics Multi-Cancer Early Screening Products, Services and Solutions
8.10.4 Singlera Genomics Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.10.5 Singlera Genomics Recent Developments
8.11 Geneseeq
8.11.1 Geneseeq Profile
8.11.2 Geneseeq Main Business
8.11.3 Geneseeq Multi-Cancer Early Screening Products, Services and Solutions
8.11.4 Geneseeq Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.11.5 Geneseeq Recent Developments
8.12 BGI Genomics
8.12.1 BGI Genomics Profile
8.12.2 BGI Genomics Main Business
8.12.3 BGI Genomics Multi-Cancer Early Screening Products, Services and Solutions
8.12.4 BGI Genomics Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.12.5 BGI Genomics Recent Developments
8.13 Burning Rock Biotech Limited
8.13.1 Burning Rock Biotech Limited Profile
8.13.2 Burning Rock Biotech Limited Main Business
8.13.3 Burning Rock Biotech Limited Multi-Cancer Early Screening Products, Services and Solutions
8.13.4 Burning Rock Biotech Limited Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.13.5 Burning Rock Biotech Limited Recent Developments
8.14 New Horizon Health Limited
8.14.1 New Horizon Health Limited Profile
8.14.2 New Horizon Health Limited Main Business
8.14.3 New Horizon Health Limited Multi-Cancer Early Screening Products, Services and Solutions
8.14.4 New Horizon Health Limited Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.14.5 New Horizon Health Limited Recent Developments
8.15 Yeasen Bio
8.15.1 Yeasen Bio Profile
8.15.2 Yeasen Bio Main Business
8.15.3 Yeasen Bio Multi-Cancer Early Screening Products, Services and Solutions
8.15.4 Yeasen Bio Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.15.5 Yeasen Bio Recent Developments
8.16 Hangzhou Aoru Biotech
8.16.1 Hangzhou Aoru Biotech Profile
8.16.2 Hangzhou Aoru Biotech Main Business
8.16.3 Hangzhou Aoru Biotech Multi-Cancer Early Screening Products, Services and Solutions
8.16.4 Hangzhou Aoru Biotech Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.16.5 Hangzhou Aoru Biotech Recent Developments
8.17 Amoy Diagnostics Co., Ltd.
8.17.1 Amoy Diagnostics Co., Ltd. Profile
8.17.2 Amoy Diagnostics Co., Ltd. Main Business
8.17.3 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Products, Services and Solutions
8.17.4 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
8.18 Genetron Health
8.18.1 Genetron Health Profile
8.18.2 Genetron Health Main Business
8.18.3 Genetron Health Multi-Cancer Early Screening Products, Services and Solutions
8.18.4 Genetron Health Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.18.5 Genetron Health Recent Developments
8.19 AnchorDx
8.19.1 AnchorDx Profile
8.19.2 AnchorDx Main Business
8.19.3 AnchorDx Multi-Cancer Early Screening Products, Services and Solutions
8.19.4 AnchorDx Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.19.5 AnchorDx Recent Developments
8.20 Surexam Bio-Tech Co.,Ltd.
8.20.1 Surexam Bio-Tech Co.,Ltd. Profile
8.20.2 Surexam Bio-Tech Co.,Ltd. Main Business
8.20.3 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Products, Services and Solutions
8.20.4 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
8.21 HaploX
8.21.1 HaploX Profile
8.21.2 HaploX Main Business
8.21.3 HaploX Multi-Cancer Early Screening Products, Services and Solutions
8.21.4 HaploX Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.21.5 HaploX Recent Developments
8.22 HefeiLaierBiotechnologyCo.,Ltd
8.22.1 HefeiLaierBiotechnologyCo.,Ltd Profile
8.22.2 HefeiLaierBiotechnologyCo.,Ltd Main Business
8.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Products, Services and Solutions
8.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Revenue (US$ Million) & (2020-2025)
8.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
9 Industry Chain Analysis
9.1 Multi-Cancer Early Screening Industrial Chain
9.2 Multi-Cancer Early Screening Upstream Analysis
9.2.1 Key Raw Materials
9.2.2 Raw Materials Key Suppliers
9.2.3 Manufacturing Cost Structure
9.3 Midstream Analysis
9.4 Downstream Analysis (Customers Analysis)
9.5 Sales Model and Sales Channels
9.5.1 Multi-Cancer Early Screening Sales Model
9.5.2 Sales Channel
9.5.3 Multi-Cancer Early Screening Distributors
10 Research Findings and Conclusion
11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Author Details
11.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Multi-Cancer Early Screening Market Trends
Table 2. Multi-Cancer Early Screening Market Drivers & Opportunity
Table 3. Multi-Cancer Early Screening Market Challenges
Table 4. Multi-Cancer Early Screening Market Restraints
Table 5. Global Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Multi-Cancer Early Screening Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Multi-Cancer Early Screening Product Type
Table 9. Key Companies Time to Begin Mass Production of Multi-Cancer Early Screening
Table 10. Global Multi-Cancer Early Screening Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-Cancer Early Screening as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Multi-Cancer Early Screening Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Multi-Cancer Early Screening Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Multi-Cancer Early Screening Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Multi-Cancer Early Screening Sales Market Share in Value by Type (2020-2025)
Table 17. Global Multi-Cancer Early Screening Sales Market Share in Value by Type (2026-2031)
Table 18. Global Multi-Cancer Early Screening Sales Value by Commercial Mode: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Multi-Cancer Early Screening Sales Value by Commercial Mode (2020-2025) & (US$ Million)
Table 20. Global Multi-Cancer Early Screening Sales Value by Commercial Mode (2026-2031) & (US$ Million)
Table 21. Global Multi-Cancer Early Screening Sales Market Share in Value by Commercial Mode (2020-2025)
Table 22. Global Multi-Cancer Early Screening Sales Market Share in Value by Commercial Mode (2026-2031)
Table 23. Global Multi-Cancer Early Screening Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 24. Global Multi-Cancer Early Screening Sales Value by Application (2020-2025) & (US$ Million)
Table 25. Global Multi-Cancer Early Screening Sales Value by Application (2026-2031) & (US$ Million)
Table 26. Global Multi-Cancer Early Screening Sales Market Share in Value by Application (2020-2025)
Table 27. Global Multi-Cancer Early Screening Sales Market Share in Value by Application (2026-2031)
Table 28. Global Multi-Cancer Early Screening Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 29. Global Multi-Cancer Early Screening Sales Value by Region (2020-2025) & (US$ Million)
Table 30. Global Multi-Cancer Early Screening Sales Value by Region (2026-2031) & (US$ Million)
Table 31. Global Multi-Cancer Early Screening Sales Value by Region (2020-2025) & (%)
Table 32. Global Multi-Cancer Early Screening Sales Value by Region (2026-2031) & (%)
Table 33. Key Countries/Regions Multi-Cancer Early Screening Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 34. Key Countries/Regions Multi-Cancer Early Screening Sales Value, (2020-2025) & (US$ Million)
Table 35. Key Countries/Regions Multi-Cancer Early Screening Sales Value, (2026-2031) & (US$ Million)
Table 36. Guardant Health Basic Information List
Table 37. Guardant Health Description and Business Overview
Table 38. Guardant Health Multi-Cancer Early Screening Products, Services and Solutions
Table 39. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Guardant Health (2020-2025)
Table 40. Guardant Health Recent Developments
Table 41. Exact Sciences Basic Information List
Table 42. Exact Sciences Description and Business Overview
Table 43. Exact Sciences Multi-Cancer Early Screening Products, Services and Solutions
Table 44. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Exact Sciences (2020-2025)
Table 45. Exact Sciences Recent Developments
Table 46. Freenome Basic Information List
Table 47. Freenome Description and Business Overview
Table 48. Freenome Multi-Cancer Early Screening Products, Services and Solutions
Table 49. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Freenome (2020-2025)
Table 50. Freenome Recent Developments
Table 51. Epiginomics AG Basic Information List
Table 52. Epiginomics AG Description and Business Overview
Table 53. Epiginomics AG Multi-Cancer Early Screening Products, Services and Solutions
Table 54. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Epiginomics AG (2020-2025)
Table 55. Epiginomics AG Recent Developments
Table 56. Bio-techne Basic Information List
Table 57. Bio-techne Description and Business Overview
Table 58. Bio-techne Multi-Cancer Early Screening Products, Services and Solutions
Table 59. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Bio-techne (2020-2025)
Table 60. Bio-techne Recent Developments
Table 61. ThriveEarlier Detection Basic Information List
Table 62. ThriveEarlier Detection Description and Business Overview
Table 63. ThriveEarlier Detection Multi-Cancer Early Screening Products, Services and Solutions
Table 64. Revenue (US$ Million) in Multi-Cancer Early Screening Business of ThriveEarlier Detection (2020-2025)
Table 65. ThriveEarlier Detection Recent Developments
Table 66. GRAIL, Inc. Basic Information List
Table 67. GRAIL, Inc. Description and Business Overview
Table 68. GRAIL, Inc. Multi-Cancer Early Screening Products, Services and Solutions
Table 69. Revenue (US$ Million) in Multi-Cancer Early Screening Business of GRAIL, Inc. (2020-2025)
Table 70. GRAIL, Inc. Recent Developments
Table 71. CellMax life Basic Information List
Table 72. CellMax life Description and Business Overview
Table 73. CellMax life Multi-Cancer Early Screening Products, Services and Solutions
Table 74. Revenue (US$ Million) in Multi-Cancer Early Screening Business of CellMax life (2020-2025)
Table 75. CellMax life Recent Developments
Table 76. Berry Genomics Basic Information List
Table 77. Berry Genomics Description and Business Overview
Table 78. Berry Genomics Multi-Cancer Early Screening Products, Services and Solutions
Table 79. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Berry Genomics (2020-2025)
Table 80. Berry Genomics Recent Developments
Table 81. Singlera Genomics Basic Information List
Table 82. Singlera Genomics Description and Business Overview
Table 83. Singlera Genomics Multi-Cancer Early Screening Products, Services and Solutions
Table 84. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Singlera Genomics (2020-2025)
Table 85. Singlera Genomics Recent Developments
Table 86. Geneseeq Basic Information List
Table 87. Geneseeq Description and Business Overview
Table 88. Geneseeq Multi-Cancer Early Screening Products, Services and Solutions
Table 89. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Geneseeq (2020-2025)
Table 90. Geneseeq Recent Developments
Table 91. BGI Genomics Basic Information List
Table 92. BGI Genomics Description and Business Overview
Table 93. BGI Genomics Multi-Cancer Early Screening Products, Services and Solutions
Table 94. Revenue (US$ Million) in Multi-Cancer Early Screening Business of BGI Genomics (2020-2025)
Table 95. BGI Genomics Recent Developments
Table 96. Burning Rock Biotech Limited Basic Information List
Table 97. Burning Rock Biotech Limited Description and Business Overview
Table 98. Burning Rock Biotech Limited Multi-Cancer Early Screening Products, Services and Solutions
Table 99. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Burning Rock Biotech Limited (2020-2025)
Table 100. Burning Rock Biotech Limited Recent Developments
Table 101. New Horizon Health Limited Basic Information List
Table 102. New Horizon Health Limited Description and Business Overview
Table 103. New Horizon Health Limited Multi-Cancer Early Screening Products, Services and Solutions
Table 104. Revenue (US$ Million) in Multi-Cancer Early Screening Business of New Horizon Health Limited (2020-2025)
Table 105. New Horizon Health Limited Recent Developments
Table 106. Yeasen Bio Basic Information List
Table 107. Yeasen Bio Description and Business Overview
Table 108. Yeasen Bio Multi-Cancer Early Screening Products, Services and Solutions
Table 109. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Yeasen Bio (2020-2025)
Table 110. Yeasen Bio Recent Developments
Table 111. Hangzhou Aoru Biotech Basic Information List
Table 112. Hangzhou Aoru Biotech Description and Business Overview
Table 113. Hangzhou Aoru Biotech Multi-Cancer Early Screening Products, Services and Solutions
Table 114. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Hangzhou Aoru Biotech (2020-2025)
Table 115. Hangzhou Aoru Biotech Recent Developments
Table 116. Amoy Diagnostics Co., Ltd. Basic Information List
Table 117. Amoy Diagnostics Co., Ltd. Description and Business Overview
Table 118. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Products, Services and Solutions
Table 119. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Amoy Diagnostics Co., Ltd. (2020-2025)
Table 120. Amoy Diagnostics Co., Ltd. Recent Developments
Table 121. Genetron Health Basic Information List
Table 122. Genetron Health Description and Business Overview
Table 123. Genetron Health Multi-Cancer Early Screening Products, Services and Solutions
Table 124. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Genetron Health (2020-2025)
Table 125. Genetron Health Recent Developments
Table 126. AnchorDx Basic Information List
Table 127. AnchorDx Description and Business Overview
Table 128. AnchorDx Multi-Cancer Early Screening Products, Services and Solutions
Table 129. Revenue (US$ Million) in Multi-Cancer Early Screening Business of AnchorDx (2020-2025)
Table 130. AnchorDx Recent Developments
Table 131. Surexam Bio-Tech Co.,Ltd. Basic Information List
Table 132. Surexam Bio-Tech Co.,Ltd. Description and Business Overview
Table 133. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Products, Services and Solutions
Table 134. Revenue (US$ Million) in Multi-Cancer Early Screening Business of Surexam Bio-Tech Co.,Ltd. (2020-2025)
Table 135. Surexam Bio-Tech Co.,Ltd. Recent Developments
Table 136. HaploX Basic Information List
Table 137. HaploX Description and Business Overview
Table 138. HaploX Multi-Cancer Early Screening Products, Services and Solutions
Table 139. Revenue (US$ Million) in Multi-Cancer Early Screening Business of HaploX (2020-2025)
Table 140. HaploX Recent Developments
Table 141. HefeiLaierBiotechnologyCo.,Ltd Basic Information List
Table 142. HefeiLaierBiotechnologyCo.,Ltd Description and Business Overview
Table 143. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Products, Services and Solutions
Table 144. Revenue (US$ Million) in Multi-Cancer Early Screening Business of HefeiLaierBiotechnologyCo.,Ltd (2020-2025)
Table 145. HefeiLaierBiotechnologyCo.,Ltd Recent Developments
Table 146. Key Raw Materials Lists
Table 147. Raw Materials Key Suppliers Lists
Table 148. Multi-Cancer Early Screening Downstream Customers
Table 149. Multi-Cancer Early Screening Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Multi-Cancer Early Screening Product Picture
Figure 2. Global Multi-Cancer Early Screening Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Multi-Cancer Early Screening Sales Value (2020-2031) & (US$ Million)
Figure 4. Multi-Cancer Early Screening Report Years Considered
Figure 5. Global Multi-Cancer Early Screening Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Multi-Cancer Early Screening Revenue in 2024
Figure 7. Multi-Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. cfDNA Methylation Picture
Figure 9. Low-pass WGS Picture
Figure 10. Protein Marker Combination Picture
Figure 11. Multi-omics Integrated Analysis Picture
Figure 12. Global Multi-Cancer Early Screening Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 13. Global Multi-Cancer Early Screening Sales Value Market Share by Type, 2024 & 2031
Figure 14. IVD（In Vitro Diagnostics） Picture
Figure 15. LDT (Laboratory Developed Test) Picture
Figure 16. Global Multi-Cancer Early Screening Sales Value by Commercial Mode (2020 VS 2024 VS 2031) & (US$ Million)
Figure 17. Global Multi-Cancer Early Screening Sales Value Market Share by Commercial Mode, 2024 & 2031
Figure 18. Product Picture of Medical Institutions
Figure 19. Product Picture of Physical Examination Centers
Figure 20. Global Multi-Cancer Early Screening Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 21. Global Multi-Cancer Early Screening Sales Value Market Share by Application, 2024 & 2031
Figure 22. North America Multi-Cancer Early Screening Sales Value (2020-2031) & (US$ Million)
Figure 23. North America Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
Figure 24. Europe Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 25. Europe Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
Figure 26. Asia Pacific Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 27. Asia Pacific Multi-Cancer Early Screening Sales Value by Region (%), 2024 VS 2031
Figure 28. South America Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 29. South America Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
Figure 30. Middle East & Africa Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 31. Middle East & Africa Multi-Cancer Early Screening Sales Value by Country (%), 2024 VS 2031
Figure 32. Key Countries/Regions Multi-Cancer Early Screening Sales Value (%), (2020-2031)
Figure 33. United States Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 34. United States Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 35. United States Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 36. Europe Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 37. Europe Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 38. Europe Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 39. China Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 40. China Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 41. China Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 42. Japan Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 43. Japan Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 44. Japan Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 45. South Korea Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 46. South Korea Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 47. South Korea Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 48. Southeast Asia Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 49. Southeast Asia Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 50. Southeast Asia Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 51. India Multi-Cancer Early Screening Sales Value, (2020-2031) & (US$ Million)
Figure 52. India Multi-Cancer Early Screening Sales Value by Type (%), 2024 VS 2031
Figure 53. India Multi-Cancer Early Screening Sales Value by Application (%), 2024 VS 2031
Figure 54. Multi-Cancer Early Screening Industrial Chain
Figure 55. Multi-Cancer Early Screening Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Multi-Cancer Early Screening in 2031?
The global market size of Multi-Cancer Early Screening in 2031 was 3346 Million USD.
Which region is expected to have the highest market share?
What was the global market size of Multi-Cancer Early Screening in 2025?
Which companies rank high in the global Multi-Cancer Early Screening market?
What is the annual compound growth rate of the global Multi-Cancer Early Screening market size from 2025 to 2031?
Related Reports
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-Cancer Early Screening market is projected to grow from US$ 1305 million in 2025 to US$ 3858 million by 2032, at a CAGR of 17.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 174
USD 4900.00
(Single User License)
Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-Cancer Early Screening market size was US$ 1305 million in 2025 and is forecast to reach a readjusted size of US$ 3858 million by 2032 with a CAGR of 17.0% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 119
USD 4250.00
(Single User License)
Global Multi-Cancer Early Screening Market Research Report 2026
The global Multi-Cancer Early Screening market was valued at US$ 1305 million in 2025 and is anticipated to reach US$ 3858 million by 2032, at a CAGR of 17.0% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 155
USD 2900.00
(Single User License)
Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1305 million in 2025 and is projected to reach US$ 3858 million, growing at a CAGR of 17.0% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 151
USD 3950.00
(Single User License)
Global Multi-Cancer Early Screening Market Research Report 2025
The global market for Multi-Cancer Early Screening was valued at US$ 1115 million in the year 2024 and is projected to reach a revised size of US$ 3346 million by 2031, growing at a CAGR of 17.0% during the forecast period.
Published Date: 2025-07-24
Pages: 103
USD 2900.00
(Single User License)
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-Cancer Early Screening market is projected to grow from US$ 1115 million in 2024 to US$ 3346 million by 2031, at a CAGR of 17.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-24
Pages: 162
USD 4900.00
(Single User License)
Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-Cancer Early Screening market size was US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 120
USD 4250.00
(Single User License)
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-Cancer Early Screening market is projected to grow from US$ 1305 million in 2025 to US$ 3858 million by 2032, at a CAGR of 17.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 174
USD 4900.00 (Single User License)Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-Cancer Early Screening market size was US$ 1305 million in 2025 and is forecast to reach a readjusted size of US$ 3858 million by 2032 with a CAGR of 17.0% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 119
USD 4250.00 (Single User License)Global Multi-Cancer Early Screening Market Research Report 2026
The global Multi-Cancer Early Screening market was valued at US$ 1305 million in 2025 and is anticipated to reach US$ 3858 million by 2032, at a CAGR of 17.0% from 2026 to 2032.
Published: 2026-03-12
Pages: 155
USD 2900.00 (Single User License)Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1305 million in 2025 and is projected to reach US$ 3858 million, growing at a CAGR of 17.0% from 2026 to 2032.
Published: 2026-03-09
Pages: 151
USD 3950.00 (Single User License)Global Multi-Cancer Early Screening Market Research Report 2025
The global market for Multi-Cancer Early Screening was valued at US$ 1115 million in the year 2024 and is projected to reach a revised size of US$ 3346 million by 2031, growing at a CAGR of 17.0% during the forecast period.
Published: 2025-07-24
Pages: 103
USD 2900.00 (Single User License)Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-Cancer Early Screening market is projected to grow from US$ 1115 million in 2024 to US$ 3346 million by 2031, at a CAGR of 17.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-24
Pages: 162
USD 4900.00 (Single User License)Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-Cancer Early Screening market size was US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 120
USD 4250.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now